We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+58.2%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$160M
AUM Growth
+$53.9M
Cap. Flow
+$1.45M
Cap. Flow %
0.91%
Top 10 Hldgs %
86.01%
Holding
55
New
3
Increased
9
Reduced
6
Closed
1

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$996K
2
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$437K
3
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$364K
4
AMRN
Amarin Corp
AMRN
+$343K
5
MYGN icon
Myriad Genetics
MYGN
+$304K

Top Sells

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$737K
2
ATRA icon
Atara Biotherapeutics
ATRA
+$372K
3
VCYT icon
Veracyte
VCYT
+$267K
4
SITO
SITO MOBILE, LTD
SITO
+$168K
5
AMAG
AMAG Pharmaceuticals
AMAG
+$152K

Sector Composition

Rank Sector Weight
1 Healthcare 96.8%
2 Energy 2.17%
3 Consumer Staples 0.09%
4 Materials 0.08%
5 Industrials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CORT icon
26
Corcept Therapeutics
CORT
$9.87B
$587K 0.37%
50,000
– –
PXD
27
DELISTED
Pioneer Natural Resource Co.
PXD
$579K 0.36%
3,800
– –
VYGR icon
28
Voyager Therapeutics
VYGR
$187M
$574K 0.36%
30,000
-3,000
-9% -$39.1K
FOLD
29
DELISTED
Amicus Therapeutics
FOLD
$517K 0.32%
38,000
– –
SLNO
30
DELISTED
Soleno Therapeutics
SLNO
$496K 0.31%
16,040
-27,733
-63% -$737K
LXRX icon
31
Lexicon Pharmaceuticals
LXRX
$1.03B
$445K 0.28%
80,000
+60,000
+300% +$364K
DOVA
32
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
$445K 0.28%
50,000
+10,000
+25% +$81.2K
ARVN icon
33
Arvinas
ARVN
$517M
$443K 0.28%
30,000
– –
ODT
34
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$442K 0.28%
20,000
– –
KPTI icon
35
Karyopharm Therapeutics
KPTI
$150M
$409K 0.26%
4,667
– –
OMED
36
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$387K 0.24%
372,557
+200,000
+116% +$163K
XNCR icon
37
Xencor
XNCR
$1.41B
$382K 0.24%
12,300
– –
CLR
38
DELISTED
CONTINENTAL RESOURCES INC.
CLR
$358K 0.22%
8,000
– –
OVV icon
39
Ovintiv
OVV
$16.5B
$344K 0.22%
9,500
-1,560
-14% -$53.5K
SIEN
40
DELISTED
Sientra, Inc.
SIEN
$343K 0.21%
4,000
– –
NKTR icon
41
Nektar Therapeutics
NKTR
$2.22B
$319K 0.2%
633
– –
DERM
42
DELISTED
Dermira, Inc.
DERM
$271K 0.17%
+20,000
New +$167K
GTHX
43
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$249K 0.16%
15,000
– –
IMGN
44
DELISTED
Immunogen Inc
IMGN
$244K 0.15%
90,000
+68,000
+309% +$295K
EQT icon
45
EQT Corp
EQT
$30.8B
$234K 0.15%
11,300
– –
YTEN
46
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
$141K 0.09%
129
+2
+2% +$2.15K
LTHM
47
DELISTED
Livent Corporation
LTHM
$123K 0.08%
10,000
– –
TGTX icon
48
TG Therapeutics
TGTX
$8.39B
$121K 0.08%
15,000
– –
XBIT icon
49
XBiotech
XBIT
$68.9M
$110K 0.07%
+10,000
New +$81.1K
CFRX
50
DELISTED
ContraFect Corporation
CFRX
$96K 0.06%
300
– –
1
2
3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q1 2019 Portfolio in Review

As of Q1 2019, Birchview Capital held 55 positions worth $160M, up 51% from $106M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Birchview Capital's Q1 2019 filing shows 3 new, 9 increased, 6 reduced and 1 closed positions. Its largest new stake was Bristol-Myers Squibb: 20,000 shares worth $954K. The largest sale was Soleno Therapeutics, an estimated $737K.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q1 2019 buy was Bristol-Myers Squibb: 20,000 shares worth $954K.
  • Birchview Capital added most to Intercept Pharmaceuticals, Inc. in Q1 2019, an estimated $437K increase.
  • Birchview Capital's biggest Q1 2019 reduction was Soleno Therapeutics, cutting an estimated $737K.
  • Birchview Capital fully exited AMAG Pharmaceuticals in Q1 2019, selling an estimated $152K.
  • Birchview Capital's ten largest holdings make up 86% of its $160M portfolio in Q1 2019.
  • Birchview Capital opened 3 new positions and closed 1 in Q1 2019.
  • Birchview Capital's portfolio value rose 51% quarter-over-quarter to $160M.

Based on Birchview Capital's 13F filing for Q1 2019, filed 3 May 2019.